{
  "abstract": "The biotechnology company Sarepta Therapeutics has decided to suspend entirely one of its treatments for Duchenne muscular dystrophy (DMD) just days after it refused a request from the US Food and Drug Administration (FDA) to pull the drug from the market.",
  "authors": [
    {
      "affiliations": [
        "Portsmouth"
      ],
      "name": "Luke Taylor"
    }
  ],
  "title": "Duchenne gene therapy halted after three deaths and company u turn",
  "uid": "feff5c15-4b4f-5645-8618-852afe799a2f"
}